ProShare Advisors’s UroGen Pharma URGN Stock Holding History

ProShare Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Buy	+7,179	New	+$195K	﹤0.01%	1500
2026 Q1	–	Sell	-8,812	Closed	-$206K	–	2029
2025 Q4	$206K	Buy	+8,812	New	+$191K	﹤0.01%	1698
2025 Q2	–	Sell	-10,279	Closed	-$114K	–	2191
2025 Q1	$114K	Sell	10,279 -2,616	-20%	-$27.9K	﹤0.01%	1809
2024 Q4	$137K	Buy	+12,895	New	+$154K	﹤0.01%	1997
2024 Q3	–	Sell	-11,888	Closed	-$199K	–	2109
2024 Q2	$199K	Buy	+11,888	New	+$169K	﹤0.01%	1531
2020 Q1	–	Sell	-7,077	Closed	-$236K	–	1572
2019 Q4	$236K	Buy	+7,077	New	+$193K	﹤0.01%	1487
2019 Q3	–	Sell	-6,068	Closed	-$218K	–	1694
2019 Q2	$218K	Sell	6,068 -887	-13%	-$32.7K	﹤0.01%	1392
2019 Q1	$257K	Buy	6,955 +1,710	+33%	+$71.7K	﹤0.01%	1336
2018 Q4	$226K	Buy	+5,245	New	+$236K	﹤0.01%	1306

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ProShare Advisors's URGN Position: Q2 2026 in Review

ProShare Advisors opened a new position in UroGen Pharma (URGN) in Q2 2026: 7,179 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #1500 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in URGN as recently as Q4 2025.

ProShare Advisors first reported a position in URGN in Q4 2018 and has held it in 9 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

ProShare Advisors held 7,179 shares of UroGen Pharma worth $264K as of Q2 2026.
UroGen Pharma was a new ProShare Advisors position in Q2 2026.
UroGen Pharma made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1500 holding.
ProShare Advisors first reported a position in UroGen Pharma in Q4 2018 and has held it in 9 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.